References
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.
- Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.
- Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40:1352–60.
- Llovet JM, Bisceglie AD, Bruix J, Kramer BS, Lencioni R, Zhu AX, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
- Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616–23.
- Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147–56.
- Landis JR, Koch GG. The measurement of observer agreement for caterogical data. Biometrics. 1977;33:159–74.
- Watanabe H, Kunitoh H, Yamamoto S, Kawasaki S, Inoue A, Hotta K, Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. Cancer Sci. 2006;97:214–18.
- Al-Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med. 2003;127:593–6.
- Hagen PJ, Hartmann IJ, Hoekstra OS, Stokkel MP, Postmus PE, Prins MH. Comparison of observer variability and accuracy of different criteria for lung scan interpretation. J Nucl Med. 2003;44:739–44.
- Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998;29:272–9.